A cancer therapy developed by Georgia State University researchers and the biotech startup Da Zen Theranostics has entered Phase 2 clinical trials. The treatment, known as DZ-002, uses targeted radiation to destroy tumors while aiming to reduce harm to healthy tissue.
Professor of Chemistry Maged Henary, associate chair of the Department of Chemistry at Georgia State, commented on the progress: “It’s deeply rewarding to see DZ-002 advance into Phase 2 trials, marking a promising step forward in cancer treatment and offering hope for improved patient outcomes. Knowing that this therapy could help someone live longer or feel even a little better during a difficult time is what drives us every day.”
DZ-002 was developed through collaboration among Georgia State University, Emory University, and Cedars-Sinai Medical Center. The technology utilizes a fluorescent dye that binds specifically to cancer cells. This compound acts both as a contrast agent for imaging and as a delivery vehicle for cancer drugs, which may allow for more precise targeting of tumors and fewer side effects.
The diagnostic innovation behind DZ-002 is based on MHI-148, a compound created by Henary. This molecule causes tumor cells to fluoresce during imaging or surgery and can be linked with chemotherapy drugs to improve accuracy in targeting cancer cells.
Yu-Ping Cheng, CEO of Da Zen Theranostics Inc., addressed the focus of upcoming trials: “Pancreatic cancer remains one of the most challenging cancers to treat, with limited options and poor patient outcomes. In our Phase 2 trials, we’re turning our focus to this notoriously tough disease with a bold goal: to extend remission and preserve quality of life for late-stage patients who have no other alternatives.” Cheng noted that existing therapies often do not adequately address these needs but said DZ-002 offers “a new approach where others have failed” due to its selective uptake by cancer cells and minimal toxicity elsewhere.
Joanne Mitchell, director of Georgia State University’s Panther Innovations, stated: “We are excited to see Da Zen Theranostics and Dr. Henary’s breakthrough treatment mark this new milestone. As another Georgia State drug enters mid-stage clinical trials we are watching closely to see how lives can be saved with this innovate treatment platform.”
Henary highlighted the lengthy research process leading up to this point: “My greatest hope for DZ-002 is that it brings new possibilities to cancer treatment and helps save patients’ lives,” he said. “It has shown potential in targeting solid tumors and lymphoma. With its progression into Phase 2 clinical trials for pancreatic tumors, I’m optimistic about its prospects.”
The Phase 2 trial will begin at HOAG Cancer Center. More information about ongoing research efforts can be found at https://research.gsu.edu/georgia-state-technology-transfer/.
For additional details about Georgia State Research initiatives visit https://research.gsu.edu/.
